KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

GoodRx Holdings (GDRX) EBIT Margin (2019 - 2025)

Historic EBIT Margin for GoodRx Holdings (GDRX) over the last 7 years, with Q3 2025 value amounting to 7.46%.

  • GoodRx Holdings' EBIT Margin fell 29900.0% to 7.46% in Q3 2025 from the same period last year, while for Sep 2025 it was 10.37%, marking a year-over-year increase of 66500.0%. This contributed to the annual value of 8.31% for FY2024, which is 119100.0% up from last year.
  • Per GoodRx Holdings' latest filing, its EBIT Margin stood at 7.46% for Q3 2025, which was down 29900.0% from 13.2% recorded in Q2 2025.
  • GoodRx Holdings' EBIT Margin's 5-year high stood at 13.2% during Q2 2025, with a 5-year trough of 21.3% in Q3 2023.
  • For the 5-year period, GoodRx Holdings' EBIT Margin averaged around 2.98%, with its median value being 5.51% (2021).
  • Over the last 5 years, GoodRx Holdings' EBIT Margin had its largest YoY gain of 2005300bps in 2021, and its largest YoY loss of -358500bps in 2021.
  • Over the past 5 years, GoodRx Holdings' EBIT Margin (Quarter) stood at 5.51% in 2021, then tumbled by -83bps to 0.94% in 2022, then plummeted by -1086bps to 9.3% in 2023, then soared by 198bps to 9.15% in 2024, then fell by -19bps to 7.46% in 2025.
  • Its EBIT Margin was 7.46% in Q3 2025, compared to 13.2% in Q2 2025 and 11.52% in Q1 2025.